Tirzepatide (API)
TDS 1112 Inquiries
2023788-19-2
Pharmaceutical Grade
99%
Hangzhou
1g;50g 100g
Yes
2026-05-08
Semaglutide,Retatrutide,Tirzepatide,Linaclotide
-
Product Details
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.
Certificates-
TDS
Basic Info-
Product Name:
Tirzepatide
Other Name:LY3298176;
CAS No.:2023788-19-2
Molecular Formula:C225H348N48O68
Molecular Weight:4813
EC Number:200-001-8
Categories:
Characteristics-
Appearance:
White to off-white
Research-
Class:
Dual agonist — GIPR, GLP-1R
Status:FDA-approved (Mounjaro / Zepbound)
Mechanism:Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.
EC50 (Human GLP1R):0.934 nM
EC50 (Human GIPR):0.0224 nM
Source:Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI
Clinical Development:NCT03954834; NCT03987919; NCT03882970; NCT03730662; NCT04039503
FDA:Mounjaro, Zepbound (approved 2022-05-13)
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Semaglutide,Retatrutide,Tirzepatide,Linaclotide
-
Location:
8th Floor, Building 2, Phase 5, Xiasha Heda Pharmaceutical Valley, Qiantang District, Hangzhou, Zhejiang Province
-
Payment Terms:
TT against copy of documents
-
Average lead Time:
7 days
-
Total Annual Revenue:
$25 million-$50 million
-
Total Employees:
301-500
-
Year of Establishment:
2019
Company Certificates-
WC
-
GMP
-
-
Inquiry History1112 Inquiries
Country Product Purchase Quantity Date Posted
France
Tirzepatide
1 KG Oct 25, 2026
United States
Tirzepatide
2.5 MG Oct 25, 2026
United Kingdom
Tirzepatide
6 MT Oct 24, 2026
Peru
tirzepatide
10 MG Oct 21, 2026
Puerto Rico
tirzepatide
40 MG Oct 21, 2026
South Africa
Tirzepatide
1 MT Oct 20, 2026
United States
Tirzepatide
5 KG Oct 20, 2026
United States
tirzepatide
30 MG Oct 20, 2026
United States
tirzepatide
30 MG Oct 19, 2026
Philippines
tirzepatide
40 MG Oct 19, 2026
United States
tirzepatide
50 MG Oct 19, 2026
United States
tirzepatide
50 MG Oct 19, 2026
United States
Tirzepatide
300 MG Oct 19, 2026
Philippines
Tirzepatide
10 PCS Oct 16, 2026
United Kingdom
Tirzepatide
1 MT Oct 16, 2026
United States
Tirzepatide 30
1 MT Oct 16, 2026
United States
Tirzepatide
2.5 Oct 13, 2026
United Kingdom
Tirzepatide
20 MG Oct 12, 2026
Netherlands
Tirzepatide
10 MT Oct 12, 2026
United States
Tirzepatide
30 MG Oct 10, 2026 Post an enquiry for this product
More from this Seller
-
-
-
Retatrutide with 99% purity GLP-1 API Powder Bulk Wholesale Raw Material
Pharmaceutical Grade / 99%
$20-26/G FOB
-
-
-
-
GHK-CU peptide API
Pharmaceutical Grade / 99%
-
-
-
-
Linaclotide with 99% purity GMP grade API Powder Bulk Wholesale Raw Material
Pharmaceutical Grade / 99%
-
-
-
-
Dulaglutide API
Pharmaceutical Grade / 99%
-
-
-
-
Melanotan I Peptide (Afamelanotide) API
Pharmaceutical Grade / 99%
-
-
-
-
Liraglutide API
/ 99%
-


